CinRx Pharma

Overview

CinRx Pharma is a biotechnology firm headquartered in Cincinnati, Ohio. It focuses on developing high-impact therapeutic solutions through a distinctive hub-and-spoke business model, where multiple subsidiaries, known as “CinCos,” are developed to tackle various high-unmet medical needs such as cardiovascular, metabolic, and gastrointestinal conditions. CinRx was founded in 2015 by Dr. Jon Isaacsohn and has successfully raised $176 million to date. This funding has supported various clinical programs and the expansion of their innovative pipeline designed to create transformative health solutions.

Recent Developments

May 2024: CinRx Pharma announced the close of a $73 million financing round, increasing their total raised funds to $176 million. The influx of capital aims to support the advancement of existing portfolio programs and explore potential new programs. This recent financial boost is expected to enable CinRx’s expansion into areas of high unmet medical need, particularly within their existing cardiovascular and metabolic therapies.
- CinDome Pharma, a CinRx portfolio company, successfully raised $40 million in a Series B extension to support trials for deudomperidone (CIN-102), designed for managing gastroparesis, a condition inadequately addressed in the U.S.
- CinFina Pharma commenced a Phase 1 Multiple Ascending Dose (MAD) trial for CIN-110, a PYY3-36 analog, as a potential treatment for obesity.
March 2024: CinDome Pharma presented encouraging data at the Digestive Disease Week Conference from their Phase 2 envision3D study of diudomperidone (CIN-102) aimed at treating diabetic gastroparesis. The trials are expected to conclude in 2025, bringing hope to patients suffering from this challenging condition.
February 2024: CinPhloro Pharma dosed the first participants in the Phase 2 enviva study for CIN-103, targeting irritable bowel syndrome with diarrhea (IBS-D). This molecule offers a pulsatile-release formulation expected to improve therapeutic exposure and efficacy.
2023: CinCor Pharma, previously part of CinRx’s portfolio, was acquired by AstraZeneca following its public debut. This acquisition confirms CinRx’s business strategy success and provides substantial financial returns to fund further expansions.

Attribute	Information
Founding Date	2015
Headquarters	Cincinnati, Ohio, USA
Founders	Dr. Jon Isaacsohn
Revenue	Not Publicly Disclosed
Profits	Not Publicly Disclosed
Key Investors	Industry Insiders, High-Net-Worth Individuals
Industry	Biotechnology, Pharmaceutical
Number of Employees	Approximately 50

Early History

CinRx Pharma was founded in 2015 by Dr. Jon Isaacsohn, drawing on decades of expertise in drug development and clinical trials. Earlier, Dr. Isaacsohn served as Chief Medical Officer for Teva Pharmaceuticals and leveraged this experience to establish a firm that would accelerate promising medicines to market. The company initially focused on acquiring underappreciated or overlooked pharmaceutical assets and redeveloping them to address new therapeutic areas, operating on an innovative portfolio model and establishing itself with significant early strategic investments.

Company Profile and Achievements

CinRx Pharma operates on a unique hub-and-spoke model, forming smaller entities to focus on individual therapeutic programs, thus maximizing the impact and efficiency of its drug development process. This methodology has allowed CinRx to successfully spin out several companies each specializing in different unmet clinical needs:

CinCor Pharma: Focused on cardio-renal conditions, it achieved a significant milestone by developing baxdrostat (CIN-107), eventually being acquired by AstraZeneca.
CinFina Pharma: Concentrates on obesity and metabolic diseases with multiple candidates, including initial trials of CIN-110, a PYY analog targeting long-duration weight loss.
CinDome Pharma and CinPhloro Pharma: Address unmet needs in gastrointestinal treatment, each advancing clinical trials for their respective conditions of gastroparesis and IBS-D.

Current Operations and Market Position

CinRx Pharma is strategically positioned in the biotechnology sector, pioneering pharmaceutical innovations across various therapeutic areas. Its unique operational structure allows for agile and focused development processes, with several sub-companies specializing in specific areas like metabolic diseases and oncology. This approach reduces risk while maximizing potential returns. Its ability to attract significant venture capital reflects strong investor confidence in its business model and market potential.

CinRx Pharma Products

CinRx and its subsidiaries are working on a comprehensive suite of therapeutic goods addressing key areas through an asset selection process agnostic to therapeutic areas, including:

Phase 3 Drug: TTP399 for Type 1 Diabetes
Phase 2 Trials: CIN-102 for Gastroparesis, CIN-103 for IBS-D
Metabolic Treatments: Targeting obesity with CIN-109, CIN-110, CIN-209, and CIN-210

Cindome Pharma

CinDome, part of CinRx Pharma's portfolio, has emerged as a leading entity in developing therapies for chronic gastroparesis. The firm has been pivotal in formulating deudomperidone (CIN-102), potentially the first approved treatment in the U.S. for gastroparesis management. The recent $40 million Series B financing supports its existing study expansion, offering new hope for millions affected by this disorder.

Cinfina Pharma

CinFina Pharma plays a crucial role within CinRx with its commitment to advancing obesity and metabolic treatments. Recent trials of CIN-110 underscore its leadership in developing novel therapeutic avenues aimed at weight management, recognizing the industry's shift towards non-traditional obesity interventions.

Conclusion

CinRx Pharma’s innovative hub-and-spoke model positions it at the forefront of biotech firms dedicated to addressing unmet medical needs. Despite focusing on diverse therapeutic areas, its streamlined development process ensures efficient use of resources and potential for breakthrough treatments. Looking forward, they aim to leverage recent capital influxes to amplify their market impact, maintaining robust strategic partnerships and expanding their therapeutic footprint across new territories and indications.